RefleXion Medical , a therapeutic oncology company pioneering biology-guided radiotherapy* ( BgRT ) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) to evaluate the safety and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with BgRT in multiple late-stage cancers, including non-small cell lung cancer (NSCLC)
May 28, 2020
· 5 min read